Page 4 - Preference Management Solution News Today

HiberCell has commenced a first-in-human Phase Ia/b clinical trial of HC-7366 to treat advanced solid tumour patients.

The UK MHRA has granted approval to commence a clinical trial of Skymount Medical’s new oral treatments for mild to moderate Covid-19.

OliPass Corporation has initiated the dosing of subjects in Phase IIa trial of pain killer OLP-1002 for osteoarthritis patients with pain.

Unlearn.AI and Merck KGaA have signed a partnership to expedite late-stage immunology trials using new designs that comprise Digital Twins.

After a series of disappointing clinical trial data in Huntington’s disease, study design changes take aim at moving the field forward.

NRx Pharmaceuticals reported that a US NIH trial analysing Zyesami to treat critical Covid-19 patients will progress to conclude enrolment.

Pardes Biosciences has reported interim results from the Phase I trial of its oral antiviral drug, PBI-0451, in healthy adult subjects.

While an obvious solution to lockdown measures, direct-to-patient remote drug delivery is still an untapped opportunity in clinical trials.

Australian fintech startup BAXE has partnered with French technology company IDEMIA and Sydney-based startup Haventec to launch the world’s first DeFi (Decentralized finance) ecosystem with facial authentication.

Eli Lilly and Evotec have signed a drug discovery partnership within the metabolic diseases field, focusing on kidney diseases and diabetes.